JP2017503479A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017503479A5 JP2017503479A5 JP2016534624A JP2016534624A JP2017503479A5 JP 2017503479 A5 JP2017503479 A5 JP 2017503479A5 JP 2016534624 A JP2016534624 A JP 2016534624A JP 2016534624 A JP2016534624 A JP 2016534624A JP 2017503479 A5 JP2017503479 A5 JP 2017503479A5
- Authority
- JP
- Japan
- Prior art keywords
- recombinant poxvirus
- ifn
- virus
- vaccinia virus
- recombinant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13005541 | 2013-11-28 | ||
| EP13005541.1 | 2013-11-28 | ||
| PCT/EP2014/075522 WO2015078856A1 (en) | 2013-11-28 | 2014-11-25 | Compositions and methods vectors for inducing an enhanced immune response using poxvirus vectors |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019235645A Division JP7050044B2 (ja) | 2013-11-28 | 2019-12-26 | ポックスウイルスベクターを用いて増強された免疫応答を誘導するための組成物及び方法ベクター |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017503479A JP2017503479A (ja) | 2017-02-02 |
| JP2017503479A5 true JP2017503479A5 (enExample) | 2017-12-21 |
| JP6641276B2 JP6641276B2 (ja) | 2020-02-05 |
Family
ID=49680779
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016534624A Active JP6641276B2 (ja) | 2013-11-28 | 2014-11-25 | ポックスウイルスベクターを用いて増強された免疫応答を誘導するための組成物及び方法ベクター |
| JP2019235645A Active JP7050044B2 (ja) | 2013-11-28 | 2019-12-26 | ポックスウイルスベクターを用いて増強された免疫応答を誘導するための組成物及び方法ベクター |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019235645A Active JP7050044B2 (ja) | 2013-11-28 | 2019-12-26 | ポックスウイルスベクターを用いて増強された免疫応答を誘導するための組成物及び方法ベクター |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US20160376596A1 (enExample) |
| EP (2) | EP3074517B1 (enExample) |
| JP (2) | JP6641276B2 (enExample) |
| KR (1) | KR102504316B1 (enExample) |
| CN (1) | CN105829537B (enExample) |
| AU (3) | AU2014356546A1 (enExample) |
| BR (1) | BR112016011866A2 (enExample) |
| CY (1) | CY1124707T1 (enExample) |
| DK (1) | DK3074517T3 (enExample) |
| EA (1) | EA039037B1 (enExample) |
| ES (1) | ES2895977T3 (enExample) |
| HU (1) | HUE056105T2 (enExample) |
| IL (1) | IL245509B (enExample) |
| LT (1) | LT3074517T (enExample) |
| MX (1) | MX377258B (enExample) |
| MY (1) | MY188100A (enExample) |
| NZ (2) | NZ719934A (enExample) |
| PT (1) | PT3074517T (enExample) |
| SI (1) | SI3074517T1 (enExample) |
| UA (1) | UA127337C2 (enExample) |
| WO (1) | WO2015078856A1 (enExample) |
| ZA (1) | ZA201603187B (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL272546B2 (en) * | 2017-08-24 | 2024-01-01 | Bavarian Nordic As | Combined therapy for the treatment of cancer with intravenous administration of recombinant MVA and antibody |
| SG11202100305SA (en) | 2018-07-13 | 2021-02-25 | Univ Arizona State | Methods of treating cancer with tnf expressing myxoma virus |
| TWI852977B (zh) | 2019-01-10 | 2024-08-21 | 美商健生生物科技公司 | 前列腺新抗原及其用途 |
| CN114615988A (zh) | 2019-09-02 | 2022-06-10 | 亚利桑那州立大学董事会 | 用黏液瘤病毒治疗癌症的新型溶瘤病毒平台 |
| EP4061405A1 (en) | 2019-11-18 | 2022-09-28 | Janssen Biotech, Inc. | Vaccines based on mutant calr and jak2 and their uses |
| EP4175664A2 (en) | 2020-07-06 | 2023-05-10 | Janssen Biotech, Inc. | Prostate neoantigens and their uses |
| WO2022009049A1 (en) | 2020-07-06 | 2022-01-13 | Janssen Biotech, Inc. | Prostate neoantigens and their uses |
| EP3957322A1 (en) * | 2020-08-19 | 2022-02-23 | Eberhard Karls Universität Tübingen Medizinische Fakultät | Recombinant poxviridae vector expressing co-stimulatory molecules |
| US20240245765A1 (en) * | 2021-05-13 | 2024-07-25 | Thomas Jefferson University | Use of Ectromelia Virus for Cancer Immunotherapy and Vaccines |
| CN115043948B (zh) * | 2022-06-24 | 2024-05-28 | 青岛硕景生物科技有限公司 | 一种猴痘病毒特异性融合蛋白抗原及其制备方法和应用 |
| GB202407035D0 (en) * | 2024-05-17 | 2024-07-03 | Uncommon Bio Ltd | RNA constructs with immune blocking agents |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5519239A (en) * | 1978-07-28 | 1980-02-09 | Green Cross Corp:The | Interferon-producing attractant |
| CA1341245C (en) | 1988-01-12 | 2001-06-05 | F. Hoffmann-La Roche Ag | Recombinant vaccinia virus mva |
| EP0575491B1 (en) | 1991-03-07 | 2003-08-13 | Virogenetics Corporation | Genetically engineered vaccine strain |
| AU713040B2 (en) | 1994-07-15 | 1999-11-18 | University Of Iowa Research Foundation, The | Immunomodulatory oligonucleotides |
| US6207646B1 (en) | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
| US6969609B1 (en) | 1998-12-09 | 2005-11-29 | The United States Of America As Represented By The Department Of Health And Human Serivces | Recombinant vector expressing multiple costimulatory molecules and uses thereof |
| US6506559B1 (en) | 1997-12-23 | 2003-01-14 | Carnegie Institute Of Washington | Genetic inhibition by double-stranded RNA |
| AU774076C (en) * | 1998-12-09 | 2005-04-14 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | A recombinant vector expressing multiple costimulatory molecules and uses thereof |
| ATE386127T1 (de) * | 1999-04-08 | 2008-03-15 | Novartis Vaccines & Diagnostic | Verbesserung der immunantwort als anwendung in impfstoff und gentherapie |
| IL145778A0 (en) | 1999-04-21 | 2002-07-25 | American Home Prod | Methods and compositions for inhibiting the function of polynucleotide sequences |
| HU230198B1 (hu) | 2000-11-23 | 2015-10-28 | Bavarian Nordic A/S | Módosított Vacciniavírus Ankara-variáns |
| EP1456230A2 (en) | 2001-12-04 | 2004-09-15 | Bavarian Nordic A/S | Flavivirus ns1 subunit vaccine |
| AU2003249059A1 (en) * | 2002-07-24 | 2004-02-09 | Arizona Board Of Regents | Use of vaccinia virus deleted for the e3l gene as a vaccine vector |
| US20050281782A1 (en) * | 2004-06-21 | 2005-12-22 | Howard Kaufman | Novel recombinant poxvirus composition and uses thereof |
| US7998733B2 (en) * | 2004-10-05 | 2011-08-16 | Merial Limited | Chimeric vectors |
| WO2006069064A2 (en) * | 2004-12-22 | 2006-06-29 | Nucleonics, Inc. | Conserved hbv and hcv sequences useful for gene silencing |
| EP2042604A1 (en) * | 2007-09-26 | 2009-04-01 | Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) | VV promoter driven overexpression of recombinant antigens |
| NZ600629A (en) | 2010-01-28 | 2014-12-24 | Bavarian Nordic As | Vaccinia virus mutants containing the major genomic deletions of mva |
-
2014
- 2014-11-25 ES ES14806215T patent/ES2895977T3/es active Active
- 2014-11-25 JP JP2016534624A patent/JP6641276B2/ja active Active
- 2014-11-25 EP EP14806215.1A patent/EP3074517B1/en active Active
- 2014-11-25 AU AU2014356546A patent/AU2014356546A1/en not_active Abandoned
- 2014-11-25 NZ NZ719934A patent/NZ719934A/en unknown
- 2014-11-25 NZ NZ759538A patent/NZ759538A/en unknown
- 2014-11-25 WO PCT/EP2014/075522 patent/WO2015078856A1/en not_active Ceased
- 2014-11-25 UA UAA201606912A patent/UA127337C2/uk unknown
- 2014-11-25 HU HUE14806215A patent/HUE056105T2/hu unknown
- 2014-11-25 LT LTEPPCT/EP2014/075522T patent/LT3074517T/lt unknown
- 2014-11-25 KR KR1020167013453A patent/KR102504316B1/ko active Active
- 2014-11-25 DK DK14806215.1T patent/DK3074517T3/da active
- 2014-11-25 US US15/039,777 patent/US20160376596A1/en not_active Abandoned
- 2014-11-25 EA EA201691120A patent/EA039037B1/ru unknown
- 2014-11-25 MY MYPI2016701914A patent/MY188100A/en unknown
- 2014-11-25 BR BR112016011866A patent/BR112016011866A2/pt not_active Application Discontinuation
- 2014-11-25 SI SI201431894T patent/SI3074517T1/sl unknown
- 2014-11-25 EP EP21190638.3A patent/EP3971298A3/en active Pending
- 2014-11-25 MX MX2016006758A patent/MX377258B/es active IP Right Grant
- 2014-11-25 PT PT148062151T patent/PT3074517T/pt unknown
- 2014-11-25 CN CN201480062145.2A patent/CN105829537B/zh active Active
-
2016
- 2016-05-05 IL IL245509A patent/IL245509B/en active IP Right Grant
- 2016-05-11 ZA ZA2016/03187A patent/ZA201603187B/en unknown
-
2019
- 2019-12-26 JP JP2019235645A patent/JP7050044B2/ja active Active
-
2020
- 2020-04-11 US US16/846,325 patent/US12644125B2/en active Active
-
2021
- 2021-02-15 AU AU2021200985A patent/AU2021200985B2/en active Active
- 2021-11-08 CY CY20211100963T patent/CY1124707T1/el unknown
-
2024
- 2024-04-30 AU AU2024202790A patent/AU2024202790B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7050044B2 (ja) | ポックスウイルスベクターを用いて増強された免疫応答を誘導するための組成物及び方法ベクター | |
| JP6818797B2 (ja) | 強靭なｔ細胞用のｐｒ１３．５プロモータ及び抗体応答 | |
| US10111946B2 (en) | Poxviral vectors for low antibody response after a first priming immunization | |
| MX2022010588A (es) | Vacuna basada en poxvirus recombinantes contra el virus sars-cov-2. | |
| JP2023515582A5 (enExample) | ||
| JP2016510989A5 (enExample) | ||
| ZA201707985B (en) | Recombinant modified vaccinia virus ankara (mva) foot and mouth disease virus (fmdv) vaccine | |
| CA2929600C (en) | Compositions and methods vectors for inducing an enhanced immune response using poxvirus vectors | |
| HK40072005A (en) | Compositions and methods for inducing an enhanced immune response using poxvirus vectors | |
| CA3009928A1 (en) | Recombinant modified vaccinia virus ankara (mva) equine encephalitis virus vaccine | |
| HK1226774A1 (en) | Compositions and methods for inducing an enhanced immune response using poxvirus vectors | |
| HK40044708A (en) | Pr13.5 promoter for robust t-cell and antibody responses |